Sutra...I have always believed that if actc could bring this technology to the clinical stage, it would dwarf everything else they had in their IP. I think we will hear more on this in the near future.
Actually, SCRMI has two focused objectives and todays PR is one of them.
Transfusable Blood Components:For decades, donor-derived supplies of transfusable blood components have failed to keep up with increasing demand. This continual shortfall has prompted efforts to develop safe and effective blood substitutes which can be produced from non-immunoreactive sources and in limitless quantities. We are exploring the utility of pluripotent stem cells to serve as an alternative source for producing various life-saving components of the blood including red blood cells (RBCs), megakaryocytes/platelets, and bone marrow repopulating cells.
Vascular Repair Cells:Several diseases, in various organ systems, are characterized by the destruction of vascular tissues and/or irreversible damage to specific endothelial cell populations. Major research efforts at SCRMI are focused on developing cell based-therapies for the repair and regeneration of damaged tissues associated with a wide variety of age-related conditions. Areas of research currently include retinal vascular, cardiovascular, and ischemic vascular repair http://www.steminternational.com/our-focus/
News 
Market Data 
Discover 
AI
